Skip to main content

MINI REVIEW article

Front. Cell. Infect. Microbiol.
Sec. Molecular Viral Pathogenesis
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1520811
This article is part of the Research Topic Exploring SARS-CoV-2 Inflammatory Responses and Potential Targets for Treatment View all 6 articles

Advancements in the development of antivirals against SARS-Coronavirus

Provisionally accepted
Mrityunjay Kumar Mrityunjay Kumar 1MIRZA SARWAR BAIG MIRZA SARWAR BAIG 2Kanchan Bhardwaj Kanchan Bhardwaj 1,3*
  • 1 Manav Rachna International Institute of Research and Studies (MRIIRS), Faridabad, Haryana, India
  • 2 Jamia Hamdard University, New Delhi, National Capital Territory of Delhi, India
  • 3 Regional Centre for Biotechnology (RCB), Faridabad, Haryana, India

The final, formatted version of the article will be published soon.

    Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) caused an outbreak in 2002-2003, spreading to 29 countries with a mortality rate of about 10%. Strict quarantine and infection control methods quickly stopped the spread of the disease. Later research showed that SARS-CoV came from animals (zoonosis) and stressed the possibility of a similar spread from host to human, which was clearly shown by the COVID-19 outbreak. The COVID-19 pandemic, instigated by SARS-CoV-2, has affected 776 million confirmed cases and more than seven million deaths globally as of Sept 15, 2024. The existence of animal reservoirs of coronaviruses continues to pose a risk of re-emergence with improved fitness and virulence.Given the high death rate (up to 70 percent) and the high rate of severe sickness (up to 68.7 percent in long-COVID patients), it is even more critical to identify new therapies as soon as possible. This study combines research on antivirals that target SARS coronaviruses that have been conducted over the course of more than twenty years. It is a beneficial resource that might be useful in directing future studies.

    Keywords: COVID-19, Long Covid, SARS coronavirus, Betacoronavirus, antivirals

    Received: 31 Oct 2024; Accepted: 02 Jan 2025.

    Copyright: © 2025 Kumar, BAIG and Bhardwaj. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Kanchan Bhardwaj, Manav Rachna International Institute of Research and Studies (MRIIRS), Faridabad, 121 004, Haryana, India

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.